

Association study of Glutathione S-Transferase polymorphisms and risk of endometriosis in an Iranian population

Mina Hassani¹ M.Sc., Kiomars Saliminejad² M.Sc., Masood Heidarizadeh¹ Ph.D., Koorosh Kamali² M.D., Ph.D., Toktam Memariani³ M.Sc., Hamid Reza Khorram Khorshid^{4,5} M.D., Ph.D.

1. Department of Biology, Faculty of Science, University of Kurdistan, Sanandaj, Iran.
2. Reproductive Biotechnology Research Center, Avicenna Research Institute (ACECR), Tehran, Iran.
3. Central Research Lab, North Khorasan University of Medical Sciences, Bojnurd, Iran.
4. Genetic Research Center, University of Social Welfare and Rehabilitation Science, Tehran, Iran.
5. Avicenna Research Institute, Shahid Beheshti University, Tehran, Iran.

Corresponding Author:

Hamid Reza Khorram Khorshid, Avicenna Research Institute, Shahid Beheshti University, Evin, Tehran, Iran. P.O.Box: 19615-1177

Email: hrkk1@uswr.ac.ir;
h.khorramkhorshid@avicenna.ac.ir
Tel: +98 (21) 22432020

Received: 2 November 2014

Revised: 1 February 2015

Accepted: 24 February 2016

Abstract

Background: Endometriosis influenced by both genetic and environmental factors. Associations of glutathione S-transferases (*GSTs*) genes polymorphisms in endometriosis have been investigated by various researchers; however, the results are not consistent.

Objective: We examined the associations of *GSTM1* and *GSTT1* null genotypes and *GSTP1* 313 A/G polymorphisms with endometriosis in an Iranian population.

Materials and Methods: In this case-control study, 151 women with diagnosis of endometriosis and 156 normal healthy women as control group were included. The genotyping was determined using multiplex PCR and PCR- RFLP methods.

Results: The *GSTM1* null genotype was significantly higher ($p=0.027$) in the cases (7.3%) than the control group (1.3%). There was no significant difference between the frequency of *GSTT1* genotypes between the cases and controls. The *GSTP1* 313 AG genotype was significantly lower ($p=0.048$) in the case (33.1%) than the control group (44.4%).

Conclusion: Our results showed that *GSTM1* and *GSTP1* polymorphisms may be associated with susceptibility of endometriosis in Iranian women.

Key words: Endometriosis, Association study, *GSTM1*, *GSTT1*, *GSTP1*, Polymorphism.

Introduction

Endometriosis is a multifactorial disease which is characterized by presence and growth of endometrial glands and stroma outside the uterine. It affects approximately 5-10% of reproductive age women in USA (1-3). Evidences of immunological, environmental, endocrine and genetic factors involved in endometriosis pathogenesis are available, however, its etiology and pathogenesis remain unknown (4, 5). Contribution of genetic factors to endometriosis pathogenesis was confirmed by higher risk of endometriosis among monozygotic twins compared to dizygotic twins as well as higher risk of recurrence in first-degree relatives (5, 6).

genome-wide association studies showed that there is remarkable consistency in endometriosis (7). Several candidate genes in

endometriosis including phase I and II detoxification genes, sex steroid pathways, cytokine signaling pathways, adhesion molecules and growth factor have been associated with endometriosis (8, 9). The glutathione S-transferases (*GSTs*) are the key phase II xenobiotic-detoxifying enzymes, which are upregulated in response to oxidative stress and overexpressed in many tumors (10, 11). The *GSTs* gene family encodes proteins that are critical for certain life processes, detoxication and toxification procedures. It is done by conjugation of reduced glutathione (GSH) with numerous substrates such as pharmaceuticals and environmental pollutants (11).

To date, the most significant evidence linking specific polymorphisms to endometriosis comes from studies investigating phase II detoxification enzymes (9). *GSTM1* and *GSTT1*, two member of GST

gene family, have null allele variants, which their homozygosity causes a complete lack of enzyme activity (12, 13). A consistent association of a *GSTT1* polymorphisms and endometriosis, with a 29% increased risk of endometriosis in *GSTT1* null deletion carriers has been reported (9). The *GSTP1* 313 A/G polymorphism would result an amino acid substitution from isoleucine to valine at codon 105, which modifies the catalytic activity and heat stability of the enzyme (14).

According to our knowledge, the results of *GSTP1* 313 A/G polymorphism and *GSTM1* null deletions with the endometriosis are not consistent. Accordingly, we investigated the association between *GSTM1*, *GSTT1* and *GSTP1* variations and susceptibility to endometriosis in Iranian women.

Materials and methods

Subjects

In this case-control study, 151 non-relative women with endometriosis were included, who referred to the Avicenna Infertility Clinic and Tehran Clinic Hospital, Tehran, Iran. The study protocol was approved by the Ethics Committee of the Avicenna Research Institute, and written informed consent was obtained from all participants. The diagnosis was made by visual inspection of the pelvic organs at laparoscopy, The sample size was estimated from previous study (15).

Endometriosis women were classified to stage I to IV according to the revised American Society for Reproductive Medicine (ASRM) classification and they were found to have minimal (stage I), mild (stage II), moderate (stage III), and severe (stage IV) of endometriosis. The controls were 156 non-relative healthy women with no history of endometriosis and without any lesion as confirmed by laparoscopy. Because stage I and II of endometriosis are commonly found in asymptomatic women, therefore, in all controls absence of endometriosis was confirmed by laparoscopy (16). These people underwent laparoscopy for conditions other than endometriosis such as benign ovarian cyst.

Genotyping

To investigate the association between *GSTM1*, *GSTT1* and *GSTP1* variations and susceptibility to endometriosis in Iranian

women, the genotyping was performed by multiplex PCR and PCR-RFLP. Genomic DNA was extracted by salting out procedure from 5 ml of peripheral blood samples (17). Two multiplex PCR reactions were designed for the analysis of *GSTM1* and *GSTT1* null genotypes. The *ZFX* (495 bp) and *GAPDH* (113 bp) genes were used as internal controls in multiplex reactions containing *GSTM1* and *GSTT1*, respectively. Multiplex PCR technique could not distinguish between wild homozygous and heterozygous genotype of the *GSTM1* and *GSTT1* genes.

Accordingly, after electrophoresis the presence of *GSTM1* and *GSTT1* bands indicate that there is at least one copy of these genes. Each multiplex PCR reaction was performed in a final volume of 25 μ l containing: 10 X PCR buffer, 1.5 mM MgCl₂, 1U Taq DNA polymerase (CinnaGen, Iran), 0.5 mM dNTPs (Fermentas, Germany), 5 pmol of each primer, 50 ng template DNA, and sterile distilled water up to 25 μ l. Amplification was performed with an initial denaturation at 94°C for 3 min, followed by 35 cycles of amplification which was performed at 94°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec and a final extension at 72°C for 5 min. The PCR products were analyzed on 1.5% agarose gels and stained with ethidium bromide. The presence of a 459 bp or 219 bp bands indicated that there is at least one copy of the *GSTT1* and *GSTM1* genes, respectively, whereas the absence of these bands indicated the null genotype for these genes (Figure 1). The primer sequences and related product sizes are shown in table I.

The *GSTP1* 313 A/G polymorphism (rs1695) was analyzed by PCR-RFLP. The PCR amplification was carried out in a reaction mixture containing 10X PCR buffer, 2 mM MgCl₂, 1U Taq DNA polymerase (CinnaGen, Iran), 0.5 mM of dNTPs, 5 pmol of each primer, 30 ng template DNA, and sterile distilled water up to 25 μ l. Amplification was performed with an initial denaturation step at 94°C for 3 min, followed by 30 cycles at 94°C for 30 sec, annealing at 62°C for 30 sec and extension at 72°C for 30 sec, and a final extension at 72°C for 5 min. The PCR products of *GSTP1* were digested with the restriction enzymes BsmAI at 37°C overnight. The 313G allele produced two fragments with the length of 83 bp and 93 bp, while the 313A allele was not digested (176 bp). DNA

fragments were subjected to 10% polyacrylamide gel electrophoresis and stained with silver nitrate (Figure 2).

Statistical analysis

Statistical analysis was performed by IBM SPSS Version 20 (IBM Corporation, Chicago, IL, USA). Genotype and allele frequencies of each variation were compared between the case and control group by Fisher's exact test, Chi-square and logistic regression analysis. $p < 0.05$ was considered statistically significant. All analyses were estimated by odds ratio and their 95% confidence intervals (CIs).

Results

Descriptive analysis of 151 endometriosis women and 156 controls showed that the mean age of endometriosis and control groups were 31.4 ± 6.0 and 29.3 ± 5.3 years old, respectively. The mean BMI in the case and control groups were 25.0 ± 4.7 and 25.6 ± 5.6 , respectively. The *GSTM1* null genotype was significantly higher ($p = 0.027$, $OR = 5.76$, 95%

CI:1.22-27.11) in the cases (7.3%) than the control group (1.3%).

This finding suggested that *GSTM1* null polymorphism may be associated with susceptibility to endometriosis. In the endometriosis group, homozygous women for the *GSTM1* null allele showed a six-fold increased risk of endometriosis than the controls (Table II). On the other hands, there was not a significant difference between the frequency of null and present genotype of *GSTT1* between the cases and controls (Table II).

Genotype distribution in the control group for the *GSTP1* 313 A/G polymorphism was in Hardy-Weinberg equilibrium ($p > 0.05$). Genotype and allele frequencies for *GSTP1* 313 A/G are summarized in table III. Our results showed that there was significant difference in the genotype distributions of *GSTP1* 313 A/G between the case and control groups. The *GSTP1* 313 A/G genotype was significantly lower ($p = 0.048$; $OR = 0.61$, 95% CI:0.37-0.99) in the case (33.1%) than the control group (44.4%).

Table I. Primer sequences and their related sizes for each polymorphism

Gene	Primer sequences (5'→3')	Size (bp)
<i>GSTP1</i> (27)	ACCCCAGGGCTCTATGGGAA	176 pb
	TGAGGGCACAAGAAGCCCCT	
<i>GSTT1</i> (27)	TTCCTTACTGGTCCTCACATCTC	459 pb
	TCACCGGATCATGGCCAGCA	
<i>GSTM1</i> (27)	GAACTCCCTGAAAAGCTAAAGC	219 pb
	GTTGGGCTCAAATATACGGTGG	
<i>ZFX</i>	ACCGTGTACTGACTGTGATTACAC	495 pb
	GCACCTCTTTGGTATCCGAGAAAGT	
<i>GAPDH</i>	CCGGGTTCACTAAGTGTCTGC	113 pb
	TTCACACCCATGACGAACAT	

Table II. Genotype distribution and allele frequency of the *GSTM1* and *GSTT1* polymorphisms in endometriosis women and controls

Gene	Genotype	Cases (n=151)	Controls (n=156)	p-value	OR (95% CI)
<i>GSTM1</i>	Present*	140 (92.8%)	150 (98.7%)	0.027**	Reference group
	Null deletion	11 (7.3%)	2 (1.3%)		5.76 (1.22-27.11)
<i>GSTT1</i>	Present*	117 (77.5%)	120 (76.9%)	0.785	Reference group
	Null deletion	34 (22.5%)	36 (23.1%)		0.93 (0.53-1.62)

* There is at least one copy of wild allele**Fisher's exact test.

Table III. Genotype distribution and allele frequency of the *GSTP1* 313A/G polymorphism in endometriosis women and controls

Genotype/Allele	Cases	Controls	p-value	OR (95% CI)
AA	85 (56.3%)	72 (47.7%)	0.048*	Reference genotype
AG	50 (33.1%)	67 (44.4%)		0.61 (0.37-0.99)
GG	16 (10.6%)	12 (7.9%)	0.863	0.93 (0.39-2.21)
A	220 (72.8%)	211 (69.9%)	0.418	Reference allele
G	82 (27.2%)	91 (30.1%)		0.864 (0.607- 1.23)

* Logistic regression ($p < 0.05$). n=151

Table IV. Summary of studies which evaluated the *GSTM1*, *GSTT1* and *GSTP1* variations in endometriosis. Positive and negative results abbreviated as P and N, respectively

No.	Country	Study	Year	SNP			Case	Control	Race
				<i>GSTT1</i>	<i>GSTM1</i>	<i>GSTP1</i>			
1	Russia	Baranov et al.	1996		P		42	67	
2	France	Baranova et al.	1999		P		65	72	
3	UK	Hadfield et al.	2001	N	N		148	148	
4	UK	Baxter et al.	2001		N		84	219	
5	Turkey	Ertunc et al.	2005			P	150	150	Caucasian
6	Iran	Hosseinzadeh et al.	2011		P		120	200	
7	Iran	Seifati et al.	2012		N		101	142	
8	Italy	Vichi et al.	2012	N	N	N	181	162	
9	Brazil	Frare et al.	2013	P	P		50	46	
10	China	Peng et al.	2003		P		76	80	
11	China	Lin et al.	2003	P	P		68	28	
12	Japan	Morizane et al.	2004	N	N		114	179	
13	Taiwanese	Hsieh et al.	2004		P		150	159	Asian
14	South Korea	Hur et al.	2004	N	N	N	194	259	
15	South Korea	Jeon et al.	2010			N	260	194	
16	Japan	Matsuzaka et al.	2012	N	N	N	100	143	
This study			2015	N	P	P	151	156	Caucasian




Figure 1. Results of *GSTT1* and *GSTM1* multiplex PCR on 1.5% agarose gels. A: Lane M: Marker 100 bp; Lane 1: DDW as negative control; Lane 3: *GSTT1* null deletion (Homozygote); Lane 2, 4, 5 and 6: At least on copy of *GSTT1*; *GAPDH*: as internal control. B: Lane M: Marker 100 bp; Lane 5: *GSTM1* null deletion (Homozygote); Lane 1-4: At least one copy of *GSTM1*; *ZFX*: as internal control.




Fig 2. Results of RCR-RFLP for *GSTP1* 313 A/G polymorphism, separated on 10% polyacrylamide gel electrophoresis. Lane M: Marker 100 bp; Lane 2 and 6: PCR product as the control for digestion; Lane 3: Wild homozygote (AA); Lane 5: Mutant homozygote (GG); Lane 1, 4 and 7: Heterozygote (AG).

Discussion

The aim of this study was to evaluate whether the *GSTM1*, *GSTT1* null genotypes and *GSTP1* 313 A/G polymorphism are associated with susceptibility to endometriosis. In Caucasians, the frequencies of homozygous deletions of *GSTM1* and *GSTT1* are approximately 50% and 10-20%, respectively. Most studies investigating the

effect of *GSTM1* and *GSTT1* null polymorphisms do not distinguish between individuals with one or two copies of the genes; therefore, the effects of functional gene dosage could not be explored (17). The *GSTP1* 313 A/G polymorphism (Ile105Val at codon 105), resulting in an enzyme with altered substrate affinity. Approximately 10% of Caucasians are homozygous for this mutation and 40% are heterozygous (18).

Our results showed that the *GSTM1* null genotype might be associated with the risk of endometriosis in Iranian women. The endometriosis women with *GSTM1* homozygous null genotype had a six-fold increased risk of developing endometriosis ($p=0.027$; $OR=5.76$). Also, *GSTP1* 313 A/G polymorphism was associated with the endometriosis, however, 313 A/G genotype had a protective effect ($p=0.048$, $OR=0.61$), which decreases the risk of the disease. In contrast, no significant differences between the *GSTT1* null deletion and endometriosis was observed. To compare our findings, we search the PubMed database for studies that examined the association between *GSTM1*, *GSTT1*, and *GSTP1* 313 A/G polymorphisms with endometriosis up to July 2014 (Table IV).

Altogether, we found 15 publications, in which nine and eight studies were performed in Caucasian and Asian populations, respectively. Briefly, positive and negative results were found in seven and six of these studies, which evaluated the *GSTM1* null genotype and endometriosis, respectively (18-23, 25-30). Only one out of five studies, in a Turkish population, reported that there is a positive association between *GSTP1* 313 A/G and endometriosis (14, 27, 28, 30, 31). Two out of seven publications found an association between *GSTT1* null genotype and the disease (21, 23, 26-30). Positive association of *GSTM1* null genotypes and endometriosis in our study is consistent with the results of Hosseinzadeh *et al* which performed an association study in an Iranian population (21). In contrast, in another study in Iranian population by Seifati *et al*, no association was found between this null polymorphism and endometriosis (32).

As table IV clearly shows, the results of association studies in different populations are inconsistent, which could be attributed to small sample sizes, poorly matched control group and heterogeneity within populations. Because minimal and mild stages of endometriosis may be found in asymptomatic women, therefore, in control group absence of endometriosis should be confirmed by laparoscopy (16). However, Morizane *et al* used umbilical cord blood from female newborn infants as population controls for an association study of *GSTM1* and *GSTT1* variations in women with endometriosis in a Japanese population (29). If the case and control groups are not well matched for ethnicity or geographic origin then false positive association may be occurred because

of the confounding effects of population stratification (33).

Two meta-analysis evaluated the glutathione S-transferase variations in endometriosis women (13, 34). Guo *et al* performed a meta-analysis involving 14 studies investigating *GSTM1* and nine *GSTT1* studies. The results of their analysis demonstrated an association of *GSTT1* polymorphism and endometriosis, with a 29% increased risk of endometriosis in individuals homozygous for *GSTT1* null genotype. They found no evidence that women with *GSTM1* null genotype have increased risk of developing endometriosis (13). However, there was evidence of publication bias in this meta-analysis, indicating that the size of the increased risk associated with the *GSTT1* deletion variant may actually be smaller or non-existent (9). In a recent meta-analysis by Chen *et al* they concluded that the *GSTP1* 313 A/G may not be associated with endometriosis risk (34).

In conclusion, the *GSTM1* and *GSTT1* null variations may be associated with the increased risk of endometriosis in Iranian population. Additional studies on different populations are necessary to further confirm the role of glutathione S-transferase variations in the pathogenesis of endometriosis.

Acknowledgments

We are grateful to patients for participating in this study. The study was supported by the Avicenna Research Institute, Tehran, Iran.

Conflict of interest

The authors report no conflicts of interest.

References

1. Baldi A, Campioni M and Signorile PG. Endometriosis: pathogenesis, diagnosis, therapy and association with cancer (review). *Oncol Rep* 2008; 19: 843-846.
2. Bulun SE. Endometriosis. *N Engl J Med* 2009; 360: 268-279.
3. Giudice LC. Clinical practice. Endometriosis. *N Engl J Med* 2010; 362: 2389-2398.
4. Bellelis P, Podgaec S and Abrao MS. Environmental factors and endometriosis. *Rev Assoc Med Bras* 2011; 57: 448-452.
5. Simpson JL, Bischoff FZ, Kamat A, Buster JE and Carson SA. Genetics of endometriosis. *Obstet Gynecol Clin North Am* 2003; 30: 21-40.
6. Trovo de Marqui AB. Genetic polymorphisms and endometriosis: contribution of genes that regulate

- vascular function and tissue remodeling. *Rev Assoc Med Bras* 2012; 58: 620-632.
7. Rahmioglu N, Nyholt DR, Morris AP, Missmer SA, Montgomery GW and Zondervan KT. Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets. *Hum Reprod Update* 2014; 20: 702-714.
 8. Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter JN, Missmer SA, et al. The search for genes contributing to endometriosis risk. *Hum Reprod Update* 2008; 14: 447-457.
 9. Tempfer CB, Simoni M, Destenaves B and Fauser BC. Functional genetic polymorphisms and female reproductive disorders: part II-endometriosis. *Hum Reprod Update* 2009; 15: 97-118.
 10. Josephy PD. Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology. *Hum Genomics Proteomics* 2010; 2010: 876940.
 11. Nebert DW and Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. *Hum Genomics* 2004; 1: 460-464.
 12. Bohanec Grabar P, Logar D, Tomsic M, Rozman B and Dolzan V. Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis. *Clin Exp Rheumatol* 2009; 27: 229-236.
 13. Guo SW. Glutathione S-transferases M1/T1 gene polymorphisms and endometriosis: a meta-analysis of genetic association studies. *Mol Hum Reprod* 2005; 11: 729-743.
 14. Ertunc D, Aban M, Tok EC, Tamer L, Arslan M and Dilek S. Glutathione-S-transferase P1 gene polymorphism and susceptibility to endometriosis. *Hum Reprod* 2005; 20: 2157-2161.
 15. Hsieh YY, Chang CC, Tsai FJ, Lin CC, Chen JM, Tsai CH. Glutathione S-transferase M1*null genotype but not myeloperoxidase promoter G-463A polymorphism is associated with higher susceptibility to endometriosis. *Mol Hum Reprod* 2004; 10: 713-717.
 16. Zondervan KT, Cardon LR and Kennedy SH. What makes a good case-control study? Design issues for complex traits such as endometriosis. *Hum Reprod* 2002; 17: 1415-1423.
 17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988; 16: 1215.
 18. Buchard A, Sanchez JJ, Dalhoff K, Morling N. Multiplex PCR detection of GSTM1, GSTT1, and GSTP1 gene variants: simultaneously detecting GSTM1 and GSTT1 gene copy number and the allelic status of the GSTP1 Ile105Val genetic variant. *J Mol Diagn* 2007; 9: 612-617.
 19. Baranov VS, Ivaschenko T, Bakay B, Aseev M, Belotserkovskaya R, Baranova H, et al. Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. *Hum Genet* 1996; 97: 516-520.
 20. Baranova H, Canis M, Ivaschenko T, Albuissou E, Bothorishvilli R, Baranov V, et al. Possible involvement of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the development of endometriosis. *Mol Hum Reprod* 1999; 5: 636-641.
 21. Frare AB, Barbosa AM, Costa IR, Souza SR, Silva RC, Bordin BM, et al. GSTM1 and GSTT1 polymorphisms in endometriosis in women from Goias, Brazil. *Genet Mol Res* 2013; 12: 2764-2670.
 22. Hosseinzadeh Z, Mashayekhi F, Sorouri ZZ. Association between GSTM1 gene polymorphism in Iranian patients with endometriosis. *Gynecol Endocrinol* 2011; 27: 185-189.
 23. Lin J, Zhang X, Qian Y, Ye Y, Shi Y, Xu K, et al. Glutathione S-transferase M1 and T1 genotypes and endometriosis risk: a case-controlled study. *Chin Med J (Engl)* 2003; 116: 777-780.
 24. Peng DX, He YL, Qiu LW, Yang F, Lin JM. [Association between glutathione S-transferase M1 gene deletion and genetic susceptibility to endometriosis]. *Di Yi Jun Yi Da Xue Xue Bao* 2003; 23: 458-462. (In Chinese)
 25. Baxter SW, Thomas EJ, Campbell IG. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. *Carcinogenesis* 2001; 22: 63-65.
 26. Hadfield RM, Manek S, Weeks DE, Mardon HJ, Barlow DH, Kennedy SH. Linkage and association studies of the relationship between endometriosis and genes encoding the detoxification enzymes GSTM1, GSTT1 and CYP1A1. *Mol Hum Reprod* 2001; 7: 1073-1078.
 27. Hur SE, Lee JY, Moon HS, Chung HW. Polymorphisms of the genes encoding the GSTM1, GSTT1 and GSTP1 in Korean women: no association with endometriosis. *Mol Hum Reprod* 2005; 11: 15-19.
 28. Matsuzaka Y, Kikuti YY, Goya K, Suzuki T, Cai LY, Oka A, et al. Lack of an association human dioxin detoxification gene polymorphisms with endometriosis in Japanese women: results of a pilot study. *Environ Health Prev Med* 2012; 17: 512-517.
 29. Morizane M, Yoshida S, Nakago S, Hamana S, Maruo T, Kennedy S. No association of endometriosis with glutathione S-transferase M1 and T1 null mutations in a Japanese population. *J Soc Gynecol Invest* 2004; 11: 118-121.
 30. Vichi S, Medda E, Ingelido AM, Ferro A, Resta S, Porpora MG, et al. Glutathione transferase polymorphisms and risk of endometriosis associated with polychlorinated biphenyls exposure in Italian women: a gene-environment interaction. *Fertil Steril* 2012; 97: 1143-1151.
 31. Jeon MJ, Choi YM, Hong MA, Lee GH, Ku SY, Kim SH, et al. No association between the GSTP1 exon 5 polymorphism and susceptibility to advanced stage endometriosis in the Korean population. *Am J Reprod Immunol* 2010; 63: 222-226.
 32. Seifati SM, Parivar K, Aflatoonian A, Dehghani Firouzabadi R, Sheikha MH. No association of GSTM1 null polymorphism with endometriosis in women from central and southern Iran. *Iran J Reprod Med* 2012; 10: 23-28.
 33. Cardon LR and Bell JL. Association study designs for complex diseases. *Nat Rev Genet* 2001; 2: 91-99.
 34. Chen X, Yan Y, Li P, Yang Z, Qin L, Mo W. Association of GSTP1 -313A/G polymorphisms and endometriosis risk: a meta-analysis of case-control studies. *Eur J Obstet Gynecol Reprod Biol* 2013; 171: 362-367.